-+ 0.00%
-+ 0.00%
-+ 0.00%
RedHill Biopharma Highlights Growth Opportunities Following Talicia Divestiture, Portfolio Expansion
Share
Listen to the news

 RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that Guy Goldberg, Chief Business Officer of RedHill Biopharma, participated in a Virtual Investor "What This Means" segment.

During the interview, Mr. Goldberg discussed the strategic evolution of RedHill's business following the successful execution of two strategic transactions with mid-size pharma companies, the divestiture of Talicia and the acquisition of commercialization rights to Rebyota® and Clenpiq®, highlighting the Company's disciplined approach to capital allocation and its transition toward a broader, revenue-generating commercial specialty pharma growth business. The discussion explored the opportunities to accelerate growth across the expanded commercial GI portfolio by leveraging the Company's existing lean infrastructure, physician relationships and established market demand, as well as ongoing execution of a roll up strategy to build upon this foundation through additional complementary products. Mr. Goldberg also addressed RedHill's priorities for the coming quarters and how disciplined commercial execution, portfolio expansion and improved operating economics could support the Company's commercial growth strategy and shareholder value.

 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending